Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Orion, Mylan, Novartis neurology news

Orion granted Mylan rights to immediately launch generic versions of Orion's Parkinson's disease drug Stalevo levodopa/carbidopa/entacapone in the U.S. The deal settles litigation filed by Orion in the U.S. District

Read the full 300 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE